A comprehensive profile of recurrent glioblastoma

Campos, Benito; Olsen, Lars Rønn; Urup, Thomas; Poulsen, Hans Skovgaard

doi:10.1038/onc.2016.85

Cited by 188 publications

(162 citation statements)

References 56 publications

Supporting

Mentioning

158

Contrasting

Unclassified

Order By: Relevance

“…Median survival (treated by current standard of care -maximal resection and radiotherapy with concomitant and adjuvant temozolomide) is 16-17 months (48), and only 9.8% of patients are still alive at five years (49). Tumor recurrence is inevitable regardless of the initial treatment and there is no widely accepted standard of treatment for recurrent GBM (50). TTFields were particularly suited to a trial in patients with GBM as the tumor is locally advancing and generally does not metastasize to distant locations, enabling full coverage of the organ's volume with TTFields.…”

Section: Clinical Trials Of Ttfields In Gbmmentioning

confidence: 99%

Tumor-Treating Fields: A Fourth Modality in Cancer Treatment

Mun

Babiker

Weinberg³

et al. 2018

Clinical Cancer Research

274

181

View full text Add to dashboard Cite

Despite major advances in therapy, cancer continues to be a leading cause of mortality. In addition, toxicities of traditional therapies pose a significant challenge to tolerability and adherence. TTFields, a noninvasive anticancer treatment modality, utilizes alternating electric fields at specific frequencies and intensities to selectively disrupt mitosis in cancerous cells. TTFields target proteins crucial to the cell cycle, leading to mitotic arrest and apoptosis. TTFields also facilitate an antitumor immune response. Clinical trials of TTFields have proven safe and efficacious in patients with glioblastoma multiforme (GBM), and are FDA approved for use in newly diagnosed and recurrent GBM. Trials in other localized solid tumors are ongoing. Clin Cancer Res; 24(2); 266-75. Ó2017 AACR.

show abstract

Section: Clinical Trials Of Ttfields In Gbmmentioning

confidence: 99%

Tumor-Treating Fields: A Fourth Modality in Cancer Treatment

Mun

Babiker

Weinberg³

et al. 2018

Clinical Cancer Research

274

181

View full text Add to dashboard Cite

show abstract

“…Even for patients with diffuse low-grade IDH-mutant gliomas (WHO grade II), although survival can be more than 10 years, the prognosis is unfavourable, as these tumours eventually progress to a high-grade malignant lesion (WHO grade III or IV) [4]. Despite significant advances in surgical and medical imaging techniques, as well as in adjuvant radio-, chemo-and immunotherapy [5][6][7][8][9][10], the inherent tendency of glioma cells to widely disseminate within normal brain parenchyma severely limits treatment responses [11][12][13]. Therefore, a better understanding of the mechanisms that trigger and govern glioma invasion is of high clinical importance for the development of more effective and less toxic therapeutic strategies.…”

Section: Introductionmentioning

confidence: 99%

The biology and mathematical modelling of glioma invasion: a review

Alfonso

Talkenberger

Seifert

et al. 2017

J. R. Soc. Interface.

183

163

View full text Add to dashboard Cite

Adult gliomas are aggressive brain tumours associated with low patient survival rates and limited life expectancy. The most important hallmark of this type of tumour is its invasive behaviour, characterized by a markedly phenotypic plasticity, infiltrative tumour morphologies and the ability of malignant progression from low-to high-grade tumour types. Indeed, the widespread infiltration of healthy brain tissue by glioma cells is largely responsible for poor prognosis and the difficulty of finding curative therapies. Meanwhile, mathematical models have been established to analyse potential mechanisms of glioma invasion. In this review, we start with a brief introduction to current biological knowledge about glioma invasion, and then critically review and highlight future challenges for mathematical models of glioma invasion.

show abstract

“…A direct relationship between the level of genetic complexity and poor efficacy of therapeutic strategies based on the "one-treatment-for-all" principle can be seen in glioblastoma, a genetically complex cancer characterized by a high degree of molecular and cellular heterogeneity. The promise of high-throughput molecularbased diagnostics as a strategy for more accurate patient stratification and prognostic staging has been recognized as a matter of urgent priority for improving the efficacy of glioblastoma therapy [4,5]. In this article, we discuss the current state, perspectives and specific challenges in molecular characterization and development of personalized approaches for treatment-refractory glioblastoma.…”

Section: Personalized Approach To Cancer Treatmentmentioning

confidence: 99%

“…There is a growing realization of the need for molecular classification as a pre-requisite to improve the diagnostic accuracy and develop treatment stratification schemes for recGB [4]. Highthroughput profiling has been instrumental in identifying four major molecular subtypes of glioblastoma termed classic, pro-neural, proliferative and mesenchymal [26,34].…”

Section: Molecular Stratification Of Recurrent Glioblasoma: Challengementioning

confidence: 99%

Perspectives and Challenges in Molecular-Based Diagnostics and Personalized Treatment for Recurrent High-Grade Gliomas

Kalasauskas¹,

Renovanz²,

Bikar³

et al. 2017

J Carcinog Mutagen

View full text Add to dashboard Cite

Glioblastoma is the most common and most malignant type of intrinsic brain tumor in adults. The standard of care for glioblastoma consists of surgical debulking followed by combined radiochemotherapy. The clinical efficacy of standard therapies for newly diagnosed glioblastomas is rather modest with the highest survival rate at 5-years being less than 10%. Inevitable recurrence after cytotoxic therapies poses the major challenge in the clinical management of high grade gliomas. For recurrent glioblastomas, there is no standard therapy with lack of level one evidence for treatment efficacy. Recent evidence indicates that post-therapy recurrence in gliomas is a consequence of a plethora of molecular and cellular factors including intratumoural heterogeneity, functional hierarchy of distinct types of glioma cells, dynamic changes in the molecular landscapes and cellular composition of the tumour during therapy and the impact of particular treatment modalities. There is an emerging consensus that molecular distinctions within and between individual tumours is an important factor determining clinical outcomes. Consequently, integrated approaches based on the combination of molecular profiling with traditional methods such as immunohistochemical phenotyping, karyotyping and/or non-quantitative methylation-specific PCR have emerged as a promising venue towards increasing the predictive value of diagnostics for malignant brain tumors. The high level of inter-and intra-tumoural molecular diversity in gliomas underscores the need of integrating high throughput molecular profiling and pharmacogenomics into a diagnostic paradigm for gliomas and raises the possibility that molecular-instructed personalized treatments may provide clinical benefit to patients with glioblastoma, particularly in the setting of post-treatment recurrence. Here we discuss potential prospects and challenges of patient-tailored diagnostics and personalized treatment strategies for recurrent glioblastomas.

show abstract

A comprehensive profile of recurrent glioblastoma

Cited by 188 publications

References 56 publications

Tumor-Treating Fields: A Fourth Modality in Cancer Treatment

Tumor-Treating Fields: A Fourth Modality in Cancer Treatment

The biology and mathematical modelling of glioma invasion: a review

Perspectives and Challenges in Molecular-Based Diagnostics and Personalized Treatment for Recurrent High-Grade Gliomas

Contact Info

Product

Resources

About